Oligonucleotide based therapeutic strategies for tackling schizophrenia - A systematic review
Keywords:Oligonucleotide; Aptamer; miRNA; Schizophrenia
Schizophrenia is a serious mental disorder that affects the quality of life of patients, and the cure for the disease is yet a mirage. Drugs are having side effects and not giving satisfying results. Recently, genes have been isolated. The role of oligonucleotide in many diseases, such as multiple sclerosis and cancer, is promising. Since oligonucleotides can modulate gene expression, these molecules can be used as drugs in several conditions which are beyond the usage of conventional drugs. They are also important in the future as therapeutic drugs like rare diseases, which are genetic and in which specific sequences of genes are to be addressed. Since they can bind to Cas9 protein, they can be used for gene editing. Even though the delivery of oligonucleotides faces some limitations, they can be delivered to targets using chemical modification, bioconjugation, and nanotechnology. Overall, they can be used in research, diagnosis, and therapy. Since they are small in size, they have target affinity. They are also cheap to synthesize and more stable than antibodies. This review summarizes the pathophysiology of schizophrenia and its current treatment, recent updates, and insights into the role of oligonucleotide and its regulation of genes. In this article, we also reviewed the genetics of schizophrenia and the possible application of oligonucleotides in the therapeutics of schizophrenia. The introduction of oligonucleotides in the therapy of schizophrenia can be a possible strategy that can be put forward in the future for the management of schizophrenia.
- 2023-10-05 (2)
- 2023-10-02 (1)
How to Cite
Copyright (c) 2023 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).